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The PMP22 gene encodes a protein integral to peripheral myelin. Its deletion leads to
hereditary neuropathy with liability to pressure palsies (HNPP). PMP22 is not expressed in
the adult central nervous system, but previous studies suggest a role in CNS myelin devel-
opment. The objective of this study was to identify potential structural and functional alter-
ations in the afferent visual system in HNPP patients.
Methods
Twenty HNPP patients and 18 matched healthy controls (HC) were recruited in a cross-
sectional study. Participants underwent neurological examination including visual acuity,
visual evoked potential (VEP) examination, optical coherence tomography (OCT), and
magnetic resonance imaging with calculation of brain atrophy, regarding grey and white
matter, and voxel based morphometry (VBM), in addition answered the National Eye Insti-
tute’s 39-item Visual Functioning Questionnaire (NEI-VFQ). Thirteen patients and 6 HC
were additionally examined with magnetic resonance spectroscopy (MRS).
Results
All patients had normal visual acuity, but reported reduced peripheral vision in comparison
to HC in the NEI-VFQ (p = 0.036). VEP latency was prolonged in patients (P100 = 103.7±5.7
ms) in comparison to healthy subjects (P100 = 99.7±4.2 ms, p = 0.007). In OCT, peripapil-
lary retinal nerve fiber layer thickness RNFL was decreased in the nasal sector (90.0±15.5
vs. 101.8±16.5, p = 0.013), and lower nasal sector RNFL correlated with prolonged VEP
latency (Rho = -0.405, p = 0.012). MRS revealed reduced tNAA (731.4±45.4 vs. 814.9
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±62.1, p = 0.017) and tCr (373.8±22.2 vs. 418.7±31.1, p = 0.002) in the visual cortex in
patients vs. HC. Whole brain volume, grey and white matter volume, VBM and metabolites
in a MRS sensory cortex control voxel did not differ significantly between patients and HC.
Conclusion
PMP22 deletion leads to functional, metabolic and macro-structural alterations in the affer-
ent visual system of HNPP patients. Our data suggest a functional relevance of these
changes for peripheral vision, which warrants further investigation and confirmation.
Introduction
The PMP22 gene on chromosome 17p11.2 encodes a 22-kD protein compound of myelinated
fibers in the peripheral nervous system [1]. PMP22 protein’s precise function is unknown.
Studies in PMP22+/- mice indicate that PMP22 haploinsufficiency predominantly affects mye-
lin junction formation or maintenance in peripheral Schwann cells, thereby impairing nerve
conduction [2,3]. Mutations in the PMP22 gene are the underlying cause of several hereditary
neuropathies (for a recent review see [4]): Gene duplication causes Charcot-Marie-Tooth dis-
ease type 1A (CMT1A) ([5,6]. Gene deletion leads to hereditary neuropathy with liability to
pressure palsies (HNPP) [7]. Point mutations can cause neuropathies with mixed phenotypes
ranging betweenCMT1A and HNPP [8].
HNPP is an episodic,multifocal peripheral neuropathy with typically recurrent transient
pressure palsies without pain. The focal motor and sensory symptoms usually occur within sin-
gle nerves [9]. Reports of regional HNPP prevalence range between 7.2 cases per 100,000 in
Northern England [10] and 16 per 100,000 in Finland [11].
In the central nervous system (CNS), PMP22 mRNA was initially detected during develop-
ment of the neural crest [12,13]. mRNA and protein were identified in the cytoplasm of CNS neu-
rons [14] and in oligodendrocytes in low concentrations [15]. In oligodendrocytes,PMP22 is
thought to be relevant for myelin regulation, and not to be a structural component of myelin [15].
That PMP22 deletion also plays a pathologic role in the CNS is supported by several studies
that found CNS involvement or white matter lesions in patients with HNPP [16–20]. Recently,
a study with 15 HNPP patients reported decreasedwhite matter brain volume, suggesting
widespread alterations in the CNS of HNPP patients [21]. Moreover, a specific affection of the
visual system has been reported in a HNPP family [22] and in a study comprising 8 HNPP
patients [23]. In both studies, a mild latency prolongation of the P100 wave in visually evoked
potentials (VEP) examinations was present in some patients.
Against these findings, the aim of our study was to comprehensively investigate a potential
involvement of the visual pathway in HNPP using a multimodal imaging and electrophysiology
approach comprising VEP, optical coherence tomography (OCT) [24] and brain magnetic res-
onance imaging (MRI), including magnetic resonance spectroscopy (MRS) in combination
with visual functional data (NEI-VFQ).
Material and Methods
Patients and Controls
For this cross-sectional study subjects were recruited from the Charité –Universitätsmedizin
Berlin’s neuroimmunology outpatient clinic and from healthy volunteers. A total of 20
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genetically confirmedHNPP patients with PMP22 deletion of chromosome 17p11.2–12 (13
female, 7 male) and 18 age- and sex-matched healthy controls (HC) were examined. One HC
was excluded due to papilledema, leaving a total of 17 HC (11 female, 6 male). Sex distribution
did not differ significantly between the groups (p = 0.985). Age of HNPP patients (41±15
years) and HC (39±15 years) was not statistically different (p = 0.784). Exclusion criteria for
patients and controls were any other neurological, ophthalmological or other disease poten-
tially causing retinal abnormalities, i.e. glaucoma and diabetes mellitus. All patients received a
neurological examination including testing for high contrast visual acuity using Snellen charts.
The study was approved by the ethics committee of the Charité –Universitätsmedizin Berlin
and was conducted in accordance with the currently applicable version of the Declaration of
Helsinki. All participants gave written informed consent.
Vision-related quality of life
Vision-related quality of life was assessed by self-administered questionnaire using the vali-
dated German 39-item version of the U.S. National Eye Institute Visual Functioning Question-
naire (NEI-VFQ39)[25] as previously described in detail [26]. The NEI-VFQ computes 12
subscores relating to different aspects of vision-related daily activities and an overall composite
score. Each score can range from 0 to 100, with a value of 100 representing the best possible
score, and a value of 0 the worst possible score for complete loss of vision-related function.
Optical Coherence Tomography
Peripapillary retinal nerve fiber layer (pRNFL) thickness and macular volume scans were
acquired using Heidelberg Spectralis spectral-domainOCT (Heidelberg Engineering,Ger-
many). pRNFL thickness was determined from a 12° circular scan with approximately 3.4 mm
diameter around the optic nerve head using the device’s standard protocol with activated eye
tracker. Whenever possible, the maximum 100 averaging frames in the automatic-real-time
mode (ART) were used. Average and papulomacular (PMB) pRNFL were directly derived
from the device’s output. pRNFL thickness of the nasal sector was calculated from the device’s
output of the nasal (N), nasal-superior (NS) and nasal-inferior (NI) sectors using the formula:
Nasal pRNFL = (N+2xNS+2xNI)/5, accounting for the twice-as-big area covered by the N sec-
tor in comparison to the NS and NI sectors.Macular volume was measured using a custom
protocol that generated 61 vertical slices (B-scans) focusing on the fovea, at scanning angle of
30°×25° and a resolution of 768 A-scans per B-scan and ART 13. Total macular volume
(TMV) was calculated by estimating the distance between the inner limiting membrane and
Bruch´s membrane in a 6 mm-diameter cylinder using the OCT software's standard segmenta-
tion algorithm. All scans were acquired by experiencedoperators and were evaluated for suffi-
cient signal strength, correct centering and segmentation based on the OSCAR-IB criteria by a
second operator [27].
Intraretinal segmentation data were taken from a manufacturer’s beta-software (Heidelberg
Eye Explorer V1.8.6.0 with Spectralis Viewing Module V6.0.0.2). This software automatically
detects boundaries between retinal layers. All automated segmentation results were manually
inspected and corrected if necessary by a single experiencedgrader. Combined ganglion cell
and inner plexiform layer (GCIP) and the inner nuclear layer (INL) were analyzed as volume
within the standard 6 mm ETDRS ring around the fovea as previously described [28]. Intraret-
inal segmentation could not be performed for three eyes from three patients, because of low
image quality. These scans were excluded from intraretinal layer analysis but included in the
pRNFL and TMV analysis.
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Visually Evoked Potentials
The DantecTM Keypoint VEP system (Natus Europe GmbH, Planegg, Germany) was used to
present a single-eye full field, black-and-white checkerboard pattern (15’/50-60’, at 1 m). Elec-
trodes were placed on Oz-Fz according to the “10–20 International System”. We recorded the
500 ms period following each visual stimulus, induced an average of 100 times for each eye and
checked for reproducibility using a second run.We used P100 latency for analysis only; P100
amplitude was not analyzed. Abnormal values were defined as the mean value + 2 standard
deviations in accordance with our clinical practice (above 111 ms). VEP were measured prior
to or on the same day as OCT.
Magnetic Resonance Imaging
MRI was performed on 16 HC and 18 HNPP patients. Subjects received a high-resolution
whole-brain scan at the Imaging Science Institute Charité-Siemens (ISI, Berlin, Germany) on a
1.5TMRI scanner (Magnetom Avanto, Siemens, Erlangen, Germany) using a T1-wmagnetiza-
tion-prepared rapid gradient echo (MPRAGE) sequence.MRI parameters were: TR = 1,900
ms, TE = 3.09 ms, TI = 1,100 ms, flip angle = 15°, direction of slice selection left -> right (sagit-
tal slicing), matrix size = 160x480x512 voxel size = 1x0.5x0.5 mm.
Brain Atrophy and Voxel Based Morphometry
Brain atrophy was assessed as normalized brain volume (NBV), normalized grey matter vol-
ume (NGMV) and normalizedwhite matter volume (NWMV) on basis of the T1-w scans
using the FSL 5.0 (FMRIB Software Library, Oxford, UK) pipeline SIENAX [29]. Prior to SIE-
NAX, each scan was cropped to an area approximating the MNI standard space template
shipped with FSL and subsequently corrected for non-uniformity using the N3 algorithm from
MIPAV version 5.4.2 [30].
Voxel-based morphometrywas performedusing VBM12 (University of Jena, Jena, Germany)
for SPM12 (Wellcome Trust Centre for Neuroimaging, London, UK). Prior to submitting the
T1w images to the VBM12 pipeline, the images were cropped to an MNI space area and reori-
ented to ensure approximate coincidence of the anterior commissure with the origin of coordi-
nates. A linear model was built for voxel-wise testing for group differences in local greymatter
density betweenHNPP patients and healthy controls. The linear model comprised age, gender
and total intracranial volume as covariates of no interest in order to mitigate any possible skew-
ing of results. Significancewas determined by family-wise error corrected results at p = 0.05.
Magnetic Resonance Spectroscopy
MRS was performed on 6 HC and 13 HNPP patients. All spectra were acquired in a single ses-
sion with MRI with a standard circular polarized head coil. Sagittal, coronal and transversal
T2-w turbo-spin-echoMR images were acquired for voxel positioning. Single-voxel 1H-spectra
were obtained using the point-resolved spectroscopy sequence (PRESS) [31] with frequency-
selective water suppression (CHESS) [32] and with the suppression-bandwidth set to 50 Hz.
An echo-time of TE = 135 ms was used to extract the signals from NAA, Cr and Cho reso-
nances. For this reason, the fit-quality for these metabolites was optimized. The repetition time
was set to TR = 3,000 ms in order to increase the signal-to-noise-ratio and to reduce interfering
T1 contrast. After 4 pre-scans, 192 acquisitions were added, resulting in an acquisition time of
9.8 min for each spectrum.Before acquisition, local shimming was performed using the unsup-
pressed water signal, followed by adjustment of the frequency-selective pulses for water sup-
pression. A voxel size of 40x20x20 mm for sensory cortex (SC) and 30x20x20 mm for visual
Afferent Visual System in HNPP
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cortex (VC) measurements delivered excellent spectral quality (Fig 1). Voxels were precisely
positioned along the mid-sagittal plane in order to minimize white matter partial volume
effects. Spectrumanalysis was performed using the LCModel software package with the stan-
dard basis set for 1.5 T and TE = 135 ms [33].
Statistical Analysis
Demographic group differences were analyzed using Student’s t-test (for age) and Pearson’s
Chi2 test (for gender). NEI-VFQ group differences were analyzed using non-parametricMann-
Whitney-U tests. Generalized estimating equation models (GEE) were used with the working
correlation matrix “Exchangeable” for comparison of OCT and VEP data between patients and
controls taking within-patient inter-eye dependencies in account. In each case, OCT/VEPmea-
surement values were used as dependent and the parameter ‘group’ as independent variables.
General linear models (GLM) were used to compare the MRI and MRSmeasurements of
groups. All GEE and GLMwere corrected for sex and age as covariates. Correlation analysis
betweenOCT and VEP parameters was performed using non-parametric Spearman’s Rho
analyses. Statistical analyses were performedwith SPSS version 22 (IBM SPSS, USA). Statistical
Fig 1. MRS voxel placement. Representative voxel placement in magnetic resonance spectroscopy in the sensory cortex (upper row) and visual cortex
(lower row). Both voxels are mixed tissue voxels comprising both grey and white matter.
doi:10.1371/journal.pone.0164617.g001
Afferent Visual System in HNPP
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significancewas achieved at p< 0.05. Measurement parameters are given in mean ± standard
deviation unless otherwise noted. No previous sample size calculation was performed. The
reader should be aware that results from this study are exploratory and all p values (except
VBM) are uncorrected for multiple comparisons.
Results
All patients had normal visual acuity and did not report any visual symptoms in the medical
examination. However, in the NEI-VFQ questionnaire asking for several aspects of vision-
related quality of life, patients scored significantly lower in the peripheral vision category than
HC, whereas all other areas were similar to HC (Table 1).
Average pRNFL, TMV, GCIP and INL were not significantly different between patients and
healthy controls (Table 2 and Fig 3). However, to further investigate a potential selective affec-
tion of peripheral vision suggested from the vision-related quality of life questionnaire we ana-
lyzed the pRNFL sections of the papulomacular bundle, which contains primarily central
vision axons, and the nasal hemisphere, which primarily contains axons from the peripheral
retina. Here, pRNFL in the PMB was significantly increased in HNPP vs. HC, whereas pRNFL
in the nasal hemisphere was significantly reduced in HNPP patients, supporting the peripheral
vision affection (Table 2). Furthermore, reduced nasal pRNFL thickness was inversely corre-
lated with increasedVEP P100 latency (Spearman’s Rho = -0.405, p = 0.012), whereas PMB
pRNFL thickness was not (p = 0.499). Noteworthy, two female patients, 41 and 71 years old,
showed bilateral below normal TMV and pRNFL values. The 71-year-old patient presented
with focal vitreous traction related damage in one eye, but no further pathologies were appar-
ent that could potentially explain these abnormal values. VEP latency was normal in these eyes
(99.4–104.0 ms).
Table 1. Vision-related quality of life.
HNPP HC MWU
Mean SD Min Max Mean SD Min Max p
NEI-VFQ39 Composite Score 88 9 72 100 92 8 68 100 0.129
General Health* 53 21 0 83 76 14 43 95 0.001
General Vision 72 15 50 95 70 16 45 95 0.856
Ocular Pain 81 17 50 100 89 14 50 100 0.133
Near Vision 89 10 63 100 91 15 46 100 0.122
Distance Vision 90 9 71 100 95 7 71 100 0.109
Social Functions 96 8 75 100 98 5 83 100 0.612
Well Being & Distress 89 11 70 100 93 10 60 100 0.214
Role Limitations 83 20 31 100 91 14 63 100 0.210
Dependency 99 3 88 100 100 2 94 100 0.704
Driving 80 17 50 100 90 13 58 100 0.100
Color Vision 98 8 75 100 98 6 75 100 0.899
Peripheral Vision 86 17 50 100 98 6 75 100 0.036
Abbreviations: NEI-VFQ39, 39-item National Eye Institute Visual Functioning Questionnaire; HC, healthy controls; MWU, Mann-Whitney U test; SD,
standard deviation.
*) The general health score asks for general non-vision-related health and is not included in the NEI-VFQ composite score. Significant p-values in bold.
VEP latency was significantly prolonged in HNPP patients (P100 = 103.7±5.7 ms) in comparison to HC (P100 = 99.7±4.2 ms, GEE B = 4.0, SE = 1.5,
p = 0.007) (Fig 2A). However, compared to normative data only one eye from one patient was out of normal range (P100 = 123 ms). Four eyes from three
patients were borderline normal (P100 > = 111 ms).
doi:10.1371/journal.pone.0164617.t001
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Normalized brain, grey matter and white matter volumes were not significantly different
between patients and healthy controls (Table 3). Voxel basedmorphometry did not reveal
any regional grey matter volume differences between patients and HC (all p> 0.05, not
shown).
MRS was only available for a subset of participants (6 HC and 13 HNPP patients), who were
similar in age (p = 0.172) and gender (p = 0.622). In the visual cortex voxel, MRS, tNAA and
tCr were significantly reduced in patients (Table 3 and Fig 2B–2D).When normalizingmetab-
olites against tCr, tCho/tCrwas increased in patients (0.200 vs. 0.183) but this difference did
not reach statistical significance (p = 0.094), probably due to error propagation, because nor-
malization to tCr introduces another error into the calculation, namely, the error of the tCr
measurement. Visual cortex tNAA (GEE B< 0.001, SE = 0.0, p = 0.266) or tCr (GEE B = 0.0,
SE = 0.0, p = 0.919) did not correlate with VEP latency in patients. MRSmetabolites in the sen-
sory cortex control voxel did not differ betweenHNPP and controls (Table 4).
Discussion
We here report functional and neurochemical involvement of the afferent visual system in
HNPP patients. Despite patients having visual acuity within normal range, patients reported
problems with peripheral vision in comparison to HC. VEP latencies were prolonged in
patients in comparison to healthy subjects. Average retinal OCT layer thicknesses in patients
did not differ from healthy subjects, but nasal pRNFL thickness, where most of the axons from
the peripheral retina run, was significantly reduced. Furthermore, reduced nasal pRNFL thick-
ness was associated with prolonged VEP latencies. MRS in a subset of participants revealed
Table 2. OCT measurements.
HNPP HC GEE
Mean SD Min Max Mean SD Min Max B SE p
pRNFL (μm) 92.9 9.1 76.0 110.0 96.5 10.0 79.0 120.0 -3.4 2.9 0.237
PMB RNFL (μm) 56.5. 10.7 27.0 78.0 51.1 7.1 39.0 64.0 5.5 2.2 0.013
Nasal RNFL (μm) 90.0 15.5 54.0 138.2 101.8 16.5 74.0 145.6 -11.7 4.7 0.013
TMV (mm) 8.65 0.48 7.73 9.39 8.73 0.28 8.26 9.41 -0.08 0.12 0.507
GCIP (mm) 1.91 0.2 1.53 2.31 1.96 0.17 1.6 2.31 -0.06 0.05 0.246
INL (mm) 0.95 0.08 0.85 1.13 0.94 0.05 0.87 1.05 <0.01 0.02 0.827
Abbreviations: HC, healthy controls; GEE, generalized estimating equation models; SD, standard deviation; B, non-standardized coefficient from GEE; SE,
standard error; pRNFL, peripapillary retinal nerve fibre layer thickness; PMB, papulomacular bundle; TMV, total macular volume; GCIP, ganglion cell and
inner plexiform layer; INL, inner nuclear layer.
doi:10.1371/journal.pone.0164617.t002
Table 3. Brain atrophy.
HNPP HC MLR
Mean SD Min Max Mean SD Min Max F p
Brain atrophy
NBV (ml) 1,558 69 1,438 1,679 1,546 77 1,423 1,682 3.488 0.081
NGMV (ml) 783 57 706 929 772 62 680 901 1.268 0.278
NWMV (ml) 775 30 718 826 774 30 718 840 2.307 0.150
Abbreviations: HC, healthy controls; MLR, multiple linear regression; SD, standard deviation; NBV, normalized brain volume; NGMV, normalized grey
matter volume; NWMV, normalized white matter volume.
doi:10.1371/journal.pone.0164617.t003
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reduced tNAA and tCr in a visual cortex voxel but not in a sensory cortex control voxel in
patients. Whole brain volume, grey and white matter volumes, regional grey matter volumes
and metabolites in a sensory cortex voxel were also comparable to healthy controls.
VEP alterations have been previously reported in a smaller study comprising 8 HNPP
patients [23]. Our study confirms these findings. Interestingly, in our patients this was associ-
ated with a mild decrease of RNFL thickness in the nasal sectors, and a mild increase of tempo-
ral RNFL in the papulomacular bundle. In normal healthy eyes, foveal or macular axons
mainly form the temporal RNFL, whereas axons from ganglion cells in the peripheral retina
run through superior, inferior and especially nasal sectors [34]. The observedVEP and OCT
alterations potentially reflect ultra-structural or functionalmyelin changes. Notably,
Fig 2. VEP and MRS. Differences in visual evoked potential (VEP) measurements and magnetic resonance spectroscopy between HNPP
patients (in red) and healthy controls (HC, in grey). A) VEP P100 latency, B) visual cortex tCho, C) visual cortex tNAA, D) visual cortex tCr. P
values are derived from multiple linear regression models (see results).
doi:10.1371/journal.pone.0164617.g002
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Fig 3. Optical Coherence Tomography. Differences in retinal optical coherence tomography measurements between HNPP patients (in red) and
healthy controls (HC, in grey). A) Peripapillary retinal nerve fiber layer thickness (pRNFL), B) pRNFL in the papulomacular bundle (PMB), C) pRNFL
in the nasal hemisphere, D) total macular volume (TMV), E) ganglion cell and inner plexiform layer (GCIP), F) inner nuclear layer (INL). P values are
derived from generalized estimating equation models.
doi:10.1371/journal.pone.0164617.g003
Afferent Visual System in HNPP
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conduction slowing in HNPP has been also shown for other cranial nerves, including the
acoustic, trigeminal and facial nerves [23,35].This is supported by studies in PMP22 heterozy-
gous mice, in which PMP22 haplodeficiency leads to conduction slowing in peripheral nerves,
pointing towards potentially similar mechanisms in CNSmyelin [2,3]. In the CNS, PMP22 is a
potential factor involved in cellular growth regulation during early development [13,12,36].
Accordingly, early disturbances of cranial nerves have been described and proposed as the
cause of symptoms like deafness in some patients with PMP22 mutations [37].
In contrast, our findings argue against a potential damage-related mechanism. Symptoms in
HNPP patients are regularly induced from damage to peripheral nerves, i.e. due to pressure on
the resp. nerves. Damage to CNSmyelin by a similar mechanism seems unlikely given the pro-
tective localization of the CNS. However, they are conceivable in the optic nerve, which is espe-
cially susceptible to stress at its exit from the eye, where it is additionally subject to eye
movements and potentially movement-induced stress. However, in this case one would have
expected pan or temporal retinal atrophy from retrograde neurodegeneration,which was
clearly not the case in our study.
Apart from the VEP results, HNPP patients also showed neurochemical alterations in the
visual cortex.We used an optimizedMRS protocol for yielding high-quality concentrations of
tNAA, tCho and tCr. Interestingly, tNAA and tCr were significantly reduced in HNPP patients
whereas tCho was not. N-Acetylaspartic acid (NAA) and N-acetylaspartylglutamic acid
(NAAG) are predominantly localized in neurons [38], which is why tNAA (NAA+NAAG) is
considered a neuronal marker. Therefore, loss of tNAA is generally interpreted as neuronal
damage or neuronal loss. In contrast, tCho is generally considered a marker for cell membrane
turnover [39]. tCr, on the other hand, is often used as a housekeepingmetabolite to such an
extent that some studies normalize other metabolites against tCr concentration [40]. When
normalizing against tCr, tCho/tCr was elevated in comparison to healthy controls, although
this difference did not reach significance. Taken together, the tNAA and tCr reduction and a
trend towards relative tCho increase suggest an altered visual cortex white and grey matter
composition, e.g. during development, rather than signs of neurodegeneration.OurMRS find-
ings therefore potentially support a role of PMP22 in CNS white matter development. This is
in line with a recent study that did not find any PMP22 expression in the adult CNS, but hypo-
myelination-sparing U fibers in brain white matter [21]. It is therefore conceivable that we
detected these previously described findings from biopsies with MRS in our study. This is sup-
ported by a recent report about fractional anisotropy abnormalities in central nervous system
white matter detectedwith diffusion tensor imaging in HNPP patients.[41] Alternatively, the
Table 4. MRS measurements.
HNPP HC MLR
Mean SD Min Max Mean SD Min Max F p
Visual cortex
tCho 74.7 5.9 65.0 85.6 77.0 14.2 64.9 104.9 0.248 0.626
tNAA 731.4 45.4 638.9 828.7 814.9 62.1 735.4 877.9 7.179 0.017
tCr 373.8 22.2 342.7 412.7 418.7 31.1 383.6 471.7 13.766 0.002
Sensory cortex
tCho 76.7 12.6 51.3 103.8 79.0 16.4 61.4 103.9 0.102 0.754
tNAA 584.8 77.2 442.7 699.6 621.7 52.0 549.6 698.8 0.017 0.898
tCr 315.8 37.8 236.7 380.8 339.6 29.9 305.2 378.9 0.335 0.572
Abbreviations: MRS, magnetic resonance spectroscopy; HC, healthy controls; MLR, multiple linear regression; SD, standard deviation.
doi:10.1371/journal.pone.0164617.t004
Afferent Visual System in HNPP
PLOS ONE | DOI:10.1371/journal.pone.0164617 October 17, 2016 10 / 13
detectedMRS alterations might reflect functional changes resulting from altered nerve conduc-
tion in HNPP patients rather than structural changes.
In contrast to Chanson et al., our patients had white matter volume measurements in the
range of healthy controls [21]. In fact, we did not find any evidence for reduced global or
regional brain volumes in our patients using SIENAX and VBM analysis.
The most important limitation of our study is the small sample size, owing to the rarity of
the disease. Additionally, MRS was only available for a subset of participants. In MRS, both
voxels were mixed tissue voxels, and this voxel composition might have been inappropriate to
reflect white matter changes in the sensory voxel adequately. It is therefore possible that similar
white matter changes are also present in the sensory cortex white matter voxel, but the mixed
voxel positioning did not include enough white matter tissue to reflect this. Importantly, we
only assessed high contrast visual acuity and subjective vision-related quality of life in this
study; methods that are able to detect subtle changes in clinical visual function should be
implemented in a future study. To confirm a structural and functional alteration of the optic
nerve with functional relevance for peripheral vision, future studies should include visual fields
and multifocal VEP. Lastly, the reader should be aware that this was an exploratory study and
our findings could be skewed by the small sample size. Independent confirmation is warranted.
In summary, we show evidence that PMP22 deletion leads to functional and metabolic alter-
ations in the CNS of HNPP patients. Taken together, our results and those of previous studies
suggest that CNS white matter, but not grey matter is altered in adult patients, even if PMP22
is not expressed in the adult CNS.
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